Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 47,537 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 47,537 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was purchased at an average price of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the acquisition, the chief executive officer now owns 213,234,014 shares of the company’s stock, valued at approximately $313,454,000.58. This trade represents a 0.02 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was bought at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

OPK opened at $1.50 on Thursday. The business’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.52. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market capitalization of $1.02 billion, a PE ratio of -7.89 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. The firm had revenue of $173.60 million for the quarter, compared to analyst estimates of $181.32 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. During the same quarter in the previous year, the firm earned ($0.11) EPS. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th.

Institutional Trading of OPKO Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPK. Rubric Capital Management LP grew its position in shares of OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. lifted its stake in OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the last quarter. PFG Investments LLC grew its holdings in OPKO Health by 9.4% during the fourth quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 99,795 shares during the period. Clearline Capital LP acquired a new position in OPKO Health during the third quarter worth approximately $1,083,000. Finally, Barclays PLC increased its position in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.